All News

FDA approved norelgestromin and ethinyl estradiol (Gwyn Lo; Viatris) as a low-dose once-weekly contraceptive patch.

Michael A. Reed, MD, MSCP, proposes a “Fourth Pillar” framework to integrate women's sexual health alongside reproduction, disease treatment, and longevity in clinical practice.

A cohort study of 15,382 mother-infant dyads found that subfecundity was independently associated with elevated autism spectrum disorder odds and behavioral problem scores in offspring, while IVF treatment showed no significant neurodevelopmental associations.

Corresponding author Cynthia Gyamfi-Bannerman, MD, MS, says late preterm hypoglycemia did not adversely affect neurodevelopment.

Natural Cycles received a sixth FDA clearance for an updated version of its fertility-tracking algorithm.

Get caught up with Contemporary OB/GYN! This list helps you navigate our top stories from the week, all in one place.

Jeffrey Chapa, MD, explains how telehealth and remote monitoring can extend maternal-fetal medicine access.

ACOG warns that CMS’ proposed G-codes for 2027 would create a dual maternity billing system, worsening disparities while increasing confusion.

Roche's cobas BV/CV assay received FDA clearance as a single-swab test for bacterial vaginosis and candida vaginitis.

Lisa A. Bukovac, DO, FACOG, explains how placental biomarker testing can identify which patients with suspected preeclampsia require hospitalization and which can be safely monitored.

A scoping review presented at ACOG 2026 by Calbeth C. Alaribe, DMSc, MPH, PA-C, found no studies examining the association between preeclampsia, eclampsia, and endometriosis among Black women.

New York’s Safe Motherhood Initiative bundle coincided with drops in SMM, DIC, and hysterectomy after postpartum hemorrhage.

Connor Frey, MD, explains why semaglutide and tirzepatide, but not liraglutide, generated menstrual adverse event signals in a FAERS pharmacovigilance analysis.

Damian Alagia, III, MD, joined Contemporary OB/GYN for a discussion on STIs in women, associated stigma, and structural barriers to testing.

Semaglutide showed broad menstrual adverse event signals in a FAERS analysis of reproductive-aged patients.

Get caught up with Contemporary OB/GYN! This list helps you navigate our top stories from the week, all in one place.

Appelbaum frames surgery as one component of endometriosis intervention, stressing ongoing postsurgical treatment given the chronic nature of the disease.

CDC data show 15.2% of US pregnant women reported current alcohol use in 2021-2024, up from 13.5% in 2018-2020.

ACOG, SWHR, and WFRC are calling on Congress to invest $20B over 10 years to close the women's health gap.

Heather Appelbaum, MD, FACOG, explains how distinguishing clinical from surgical diagnosis of endometriosis can enable earlier intervention, in a discussion of her NASPAG presentation.

According to Beth Ann Clayton, DNP, CRNA, FAANA, FAAN, maintaining patients with substance use disorder on methadone or buprenorphine is a critical component of preoperative planning.

IGFBP4/SHBG screen-guided care cut NICU admissions from 16.4% to 12.8% in nulliparous PRIME trial participants.

One in 3 US women aged 35 and older is unsure if they’re in perimenopause, driven by symptom confusion and care barriers.

Kate McLean, MD, describes how newly defined bacterial vaginosis subtypes could validate patient symptoms and inform treatment.

Alcohol use increased from 8% to 44% postpartum among pregnant people with HIV, with distinct risk factors identified for alcohol vs cannabis use.

The phase 4 study's oversampling of moderate PPD patients, showing a nearly 9-point EPDS drop by day 15, helps close a gap left by trials that enrolled predominantly severe cases.

Roshni Koli, MD, describes how embedding mental health care within the ob-gyn setting drove high engagement and rapid symptom remission in a perinatal collaborative care study.

A large Korean birth cohort found a modest relative increase in pediatric IBD and Crohn disease risk after prenatal PPI/H2RA exposure, but absolute risk differences were under 1 case per 1000 children.